Direct‐Acting Antiviral Therapy and Hepatocellular Carcinoma in Captive Chimpanzees With Long‐Standing Chronic Hepatitis C Virus Infection
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.71074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Satoshi Hirata und 4 weiteren Autor:innen. Beteiligte Einrichtung: Wildlife Research Center, Kyoto University, Kyoto, Kyoto, Japan. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Antiviral Agents, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wildlife Research Center of Kyoto University, Research Program on Hepatitis from the Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Chimpanzees are the only non‐human species susceptible to hepatitis C virus (HCV) infection and have served as models in HCV pathogenesis and antiviral drug development. Despite this, the long‐term clinical consequences of chronic infection and therapeutic efficacy of direct‐acting antivirals (DAAs) in this species are poorly documented. We evaluated the virologic, biochemical, and clinical outcomes of DAA therapy in eight captive chimpanzees with experimental HCV infection, with a median infection duration of 36 years (range, 25–43). Seven individuals received glecaprevir/pibrentasvir (GLE/PIB) and one individual received sequential sofosbuvir/velpatasvir/ribavirin followed by GLE/PIB. Six individuals achieved sustained virologic response (SVR), however, hepatocellular carcinoma (HCC) was detected in three of the six SVR achievers, one in the absence of histological cirrhosis. Two chimpanzees experienced virologic failure: one developed NS5A‐P32del following daclatasvir/asunaprevir exposure and relapsed despite sequential regimens, and another harbored dual NS5A mutations (L31F/Y93H) with persistent high‐level viremia. These findings demonstrate that DAAs effectively eradicate long‐standing HCV infection in chimpanzees, paralleling therapeutic outcomes observed in humans. Cases in this study also show that HCV‐infected chimpanzees, like humans, are susceptible to HCC in the late stages of chronic infection. We recommend lifelong HCC surveillance for all HCV‐exposed chimpanzees.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wildlife Research Center, Kyoto University, Kyoto, Kyoto, Japan.
- Department of Gastroenterology and Hepatology, Kumamoto University Hospital, Kumamoto, Kumamoto, Japan.
ORCID-Profile: Yasuhito Tanaka
Förderung
- Wildlife Research Center of Kyoto University
- Research Program on Hepatitis from the Japan Agency for Medical Research and Development
Zitieren
APA
Hirata, S., Nogami, E., Udono, T., Fujisawa, M., & Tanaka, Y. (2026). Direct‐Acting Antiviral Therapy and Hepatocellular Carcinoma in Captive Chimpanzees With Long‐Standing Chronic Hepatitis C Virus Infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.71074
Vancouver
Hirata S, Nogami E, Udono T, Fujisawa M, Tanaka Y. Direct‐Acting Antiviral Therapy and Hepatocellular Carcinoma in Captive Chimpanzees With Long‐Standing Chronic Hepatitis C Virus Infection. Journal of Medical Virology. 2026. doi:10.1002/jmv.71074
BibTeX
@article{Hirata2026,
author = {Hirata, Satoshi and Nogami, Etsuko and Udono, Toshifumi and Fujisawa, Michiko and Tanaka, Yasuhito},
title = {Direct‐Acting Antiviral Therapy and Hepatocellular Carcinoma in Captive Chimpanzees With Long‐Standing Chronic Hepatitis C Virus Infection},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.71074}
}
EUVIMED